The effects of Eculizumab on the pathology of malignant atrophic papulosis Academic Article uri icon


MeSH Major

  • Antibodies, Monoclonal, Humanized
  • Malignant Atrophic Papulosis


  • Complement activation and enhanced endothelial cell apoptosis play an important role in the thrombotic complications of MAP. However, the larger vessel proliferative intimal changes appear to be independent of complement activation and may be on the basis of other upstream mechanisms. Monitoring C5b-9 deposition in tissue is likely not of great value in assessing treatment response to eculizumab given the persistence of C5b-9 in tissue for several months despite clinically effective C5 blocking therapy. A more integrated approach addressing upstream and downstream pathways in addition to those attributable to complement activation are critical for the successful treatment of MAP. Eculizumab may be used as salvage therapy in critically ill patients with thrombotic microangiopathy.

publication date

  • November 26, 2013



  • Academic Article



  • eng

PubMed Central ID

  • PMC3879088

Digital Object Identifier (DOI)

  • 10.1186/1750-1172-8-185

PubMed ID

  • 24279613

Additional Document Info

start page

  • 185


  • 8


  • 1